Embio
Mumbai, India· Est.
Embio delivers GMP‑compliant small‑molecule APIs and specialty chemicals via advanced GMO‑based biotransformation platforms.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Embio delivers GMP‑compliant small‑molecule APIs and specialty chemicals via advanced GMO‑based biotransformation platforms.
PharmaceuticalsNutraceuticalsCosmeticsAgriculture
Technology Platform
Proprietary GMO biotransformation platform using engineered bacterial and fungal strains for scalable synthesis of chiral APIs, advanced intermediates, and controlled substances.
Opportunities
Expanding demand for chiral APIs and sustainable bioprocessing, plus the niche market for regulated controlled‑substance intermediates, offers strong growth potential.
Risk Factors
Regulatory scrutiny of GMO processes, supply‑chain disruptions, and competition from larger, diversified CDMO providers could impact market share.
Competitive Landscape
Embio competes with Indian CDMOs such as Jubilant Biosys and Suven, differentiating itself through its synthetic‑biology platform and capability to manufacture Schedule‑1/2 substances.